<DOC>
	<DOC>NCT02028533</DOC>
	<brief_summary>This is a pilot feasibility study assessing the tolerability of chronic administration of intranasal oxytocin to patients receiving methadone at an opioid replacement clinic who are actively using cocaine.</brief_summary>
	<brief_title>Cocaine Opioid Oxytocin Option - Limited</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Cocaine</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>Enrolled as a patient in the San Francisco General Hospital Opioid Treatment Outpatient Program Stable dose of methadone for at least the past two weeks At least one routine urine toxicology screen positive for cocaine in the past month Positive urine pregnancy test Use of illicit drugs in the past month (with the exception of cocaine or cannabis) Currently meets Diagnostic and Statistical Manual5 (DSMV) criteria for severe major depressive disorder with suicidal thoughts or actions History of psychotic or moderatesevere alcohol use disorder as defined by DSMV criteria Severe neuropsychological disorder, brain trauma, epilepsy Sensitivity to preservatives (in particular E 216, E 218 and chlorobutanol hemihydrate) Nasal obstruction, discharge, or bleeding Habitually drinks large volumes of water Taking testosterone, estrogen/progesterone supplement, or serotonin1a receptor agonists/antagonists</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>addiction</keyword>
	<keyword>oxytocin</keyword>
	<keyword>tolerability</keyword>
</DOC>